Rickinson A B, Lee S P, Steven N M
CRC Institute for Cancer Studies, Clinical Research Block, The Medical School, University of Birmingham, Edgbaston, B15 2TJ, UK.
Curr Opin Immunol. 1996 Aug;8(4):492-7. doi: 10.1016/s0952-7915(96)80036-7.
Epstein-Barr virus induces a potent cytotoxic T lymphocyte response in man that is preferentially directed towards a particular subset of the virus latent cycle antigens; the immunodominance of these proteins, apparent in both primary and memory responses, may reflect some differential access to the HLA class I processing pathway. Effector cells recognizing these immunodominant antigens can reverse the growth of virus-induced lymphoproliferative lesions in immunosuppressed patients; however, responses to some of the subdominant latent proteins will be needed to target other virus-positive tumours.
